<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344627</url>
  </required_header>
  <id_info>
    <org_study_id>ID07-60-19</org_study_id>
    <nct_id>NCT03344627</nct_id>
  </id_info>
  <brief_title>Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients</brief_title>
  <official_title>Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis and septic shock patients are considered to have a high risk of complications and
      death. Appropriate antimicrobial therapy plays an important role in determining outcomes in
      septic patients. However, pathophysiologic changes associated with critical illness have an
      impact on pharmacokinetics of antimicrobials. In addition, increasing bacterial resistance is
      also a growing concern, especially in intensive care units., Consequently, standard
      antimicrobial dose may not be sufficient to achieve pharmacokinetic/pharmacodynamic target in
      sepsis and septic shock patients. The purpose of this study is to compare a therapy between
      meropenem standard dose and meropenem high dose in the treatment of sepsis and septic shock
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA score change</measure>
    <time_frame>Change from Baseline SOFA score at day 4</time_frame>
    <description>The Sequential organ failure assessment (SOFA) score describe the time course of multiple organ dysfunction.
The SOFA score is composed of scores for six organ systems (respiratory, cardiovascular, neurological, hepatic, renal and coagulation).
The function of six organ systems is scored from 0 (no organ dysfunction) to 4 (severe organ dysfunction), and the individual organ scores are then summed to a total score between 0 and 24.
Primary outcome is assessing change between SOFA score at baseline and SOFA score at day 4 after treatment by meropenem</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>In hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>Day 3, 5, 7, 10 and 14</time_frame>
    <description>Composite of:
Persistent fever and/or
Stable or increased white blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure</measure>
    <time_frame>Day 3, 5, 7, 10 and 14</time_frame>
    <description>Elimination of the study entry pathogen within 14 days after received meropenem
Bacteremia: no growth in blood cultures
Intra-abdominal infection: no growth in blood cultures
UTI: uropathogen growth of less than 10^4 CFU/mL in women or less than 10^3 CFU/mL in men
HAP/VAP: pathogen in sputum culture growth of less than 10^3 CFU/mL
SSTI: no growth in blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressor agents</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Time interval (day) from time of vasopressor agents initiation to time to vasopressor agents discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilator</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Time interval (day) of mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Time interval (day) from ICU admission (after randomization) to ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Time interval (day) from hospital admission (after randomization) to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%T &gt; MIC</measure>
    <time_frame>Day 1</time_frame>
    <description>% time of meropenem concentration above MIC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Critical Illness</condition>
  <condition>Carbapenem</condition>
  <condition>Pharmacokinetic</condition>
  <condition>Pharmacodynamic</condition>
  <condition>Clinical Outcome</condition>
  <condition>Organ Failure, Multiple</condition>
  <condition>Morality</condition>
  <arm_group>
    <arm_group_label>Meropenem standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 1 g every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 2 g every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem standard dose</intervention_name>
    <description>Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.
Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection.</description>
    <arm_group_label>Meropenem standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem high dose</intervention_name>
    <description>Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.
Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection</description>
    <arm_group_label>Meropenem high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years and older) with sepsis and/or septic shock according to SEPSIS-3
             criteria and receive meropenem within 1 hour after diagnosis

          -  Informed consent signed by patient or their legally authorized representative

        Exclusion Criteria:

          -  Subjects with infective endocarditis

          -  Subjects with central nervous system infection

          -  Subjects who requires surgical condition within 72 hours after randomization

          -  Subjects on extracorporeal membrane oxygenation (ECMO) within 3 days after
             randomization

          -  Subjects with active seizure

          -  History of receiving meropenem within 1 week prior to randomization

          -  Pregnancy women and lactation

          -  Known allergy to meropenem

          -  Not complete a 72-hour course of empirical meropenem treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tospon Lertwattanachai, B.sc.(Pharm)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy, Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tospon Lertwattanachai, B.sc.(Pharm)</last_name>
    <phone>874979060</phone>
    <email>L.pon35@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pitchaya Dilokpattanamongkol, BCPS, BCCCP</last_name>
    <phone>824516551</phone>
    <email>Pitchaya.dil@mahidol.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tospon Lertwattanachai, B.sc.(Pharm)</last_name>
      <phone>874979060</phone>
      <email>L.pon35@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pitchaya Dilokpattanamongkol, BCPS, BCCCP</last_name>
      <phone>824516551</phone>
      <email>Pitchaya.dil@mahidol.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tospon Lertwattanachai, B.sc.(Pharm)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, Jullangkoon M, Samaeng M. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995-3001. doi: 10.1128/AAC.04166-14. Epub 2015 Mar 9.</citation>
    <PMID>25753628</PMID>
  </reference>
  <reference>
    <citation>Roberts JA, Kumar A, Lipman J. Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Crit Care Med. 2017 Feb;45(2):331-336. doi: 10.1097/CCM.0000000000002210.</citation>
    <PMID>28098629</PMID>
  </reference>
  <reference>
    <citation>Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016 May 4;5:15. doi: 10.1186/s13756-016-0115-6. eCollection 2016.</citation>
    <PMID>27148448</PMID>
  </reference>
  <reference>
    <citation>Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014 Nov 20;77:3-11. doi: 10.1016/j.addr.2014.07.006. Epub 2014 Jul 15. Review.</citation>
    <PMID>25038549</PMID>
  </reference>
  <reference>
    <citation>Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015 Feb 16;19:63. doi: 10.1186/s13054-015-0795-y. Review.</citation>
    <PMID>25888181</PMID>
  </reference>
  <reference>
    <citation>Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995 Apr;28(4):275-86. Review.</citation>
    <PMID>7648757</PMID>
  </reference>
  <reference>
    <citation>de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017 Feb 24;21(1):38. doi: 10.1186/s13054-017-1609-1.</citation>
    <PMID>28231816</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Tospon Lertwattanachai</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

